November 18, 2019 at 7:00 AM EST
- S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community setting
- XENLETA™ has a novel mechanism of action that is different than all other antibiotics, has been shown to be associated with a very low rate of resistance, and no cross resistance with other antibiotics commonly prescribed for community-acquired bacterial pneumonia
- First oral and IV antibiotic in the pleuromutilin class offers a targeted spectrum, short-course treatment option to fight drug-resistant pathogens, including S. pneumoniae
DUBLIN, Ireland, Nov. 18, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, emphasized the significance of the new updated report from the Centers for Disease Control and Prevention (CDC) concerning the rise of antibiotic resistance. Nabriva specifically commended the CDC for recognizing the need to do more in the community setting where rapid detection and prevention strategies can help curb the “serious threat” of drug-resistant Streptococcus pneumoniae. XENLETA™ (lefamulin), the first oral and IV treatment in the pleuromutilin class, is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) which affects more than five million Americans. CABP is associated with significant morbidity and mortality, and XENLETA provides a critically needed alternative treatment option to reduce the growing resistance to commonly prescribed treatments for this serious infectious disease. […]
Given the increasing rate of drug resistance to macrolides and safety concerns related to fluoroquinolones and beta-lactams, XENLETA offers CABP patients an effective and well tolerated alternative treatment option with the potential to address the limitations of existing agents. XENLETA has a novel mechanism of action that targets a binding site on bacteria that is different from existing antibiotics which has been shown to result in no cross resistance to other antibiotic classes commonly prescribed for CABP and a low potential for the development of resistance. XENLETA is also convenient for patients being treated in the hospital, transitioning treatment out of the hospital or initiating treatment in the community.
Full PR available here